Previous 10 | Next 10 |
home / stock / wxibf / wxibf news
2023-12-10 02:15:00 ET Summary Shanghai Abbisko Therapeutics has sold greater China commercialization rights for pimicotinib to Germany's Merck in a $605 million deal. Xtalpi, a China-US AI drug discovery company, has filed for a Hong Kong IPO after raising $780 million in venture...
2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...
2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...
2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...
2023-10-08 09:40:00 ET Summary Jiangsu QYuns Therapeutics has filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Taiwan’s PharmaEssentia has acquired a myeloid immune checkpoin...
2023-09-08 00:03:09 ET Summary The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. ...
2023-07-19 05:32:00 ET Summary The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs. WuXi XDC has filed for a Hong Kong IPO, calling itself the world’s second largest provid...
2023-06-14 06:28:00 ET Summary We’ve seen signs of improvement that are positive for the Chinese internet services sector, but that space also continues to be a place of extreme competitive aggression. As a result of the creation of economic zones, increased availability of...
2023-05-08 14:56:19 ET Summary WuXi Biologics (Cayman) Inc.'s short-term and mid-term financial guidance suggests that the company's revenue and earnings growth rates will be slower than what they were in recent years. Potential financing difficulties for the company's customers a...
2023-05-04 05:21:00 ET Summary Baron Emerging Markets Fund gained 2.68% (Institutional Shares) during the first quarter of 2023, while its principal benchmark Index, the MSCI EM Index, returned 3.96%. The Fund may invest in companies of any market capitalization, and we have gener...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc Company Name:
WXIBF Stock Symbol:
OTCMKTS Market:
U.S. intelligence officials have informed senators that WuXi AppTec Co Ltd (OTC:WXIBF), a Chinese pharmaceutical company, allegedly transferred U.S...
The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as "...